• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?肝切除术作为肝硬化合并肝细胞癌患者肝移植的过渡手段:一种合理的策略?
Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9. doi: 10.1097/01.sla.0000090449.87109.44.
2
Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis.初始切除肝癌后再移植的益处:一项意向治疗分析。
Hepatology. 2012 Jan;55(1):132-40. doi: 10.1002/hep.24680.
3
Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation.可移植性肝细胞癌的肝切除术:长期生存及二次肝移植的作用
Ann Surg. 2009 Nov;250(5):738-46. doi: 10.1097/SLA.0b013e3181bd582b.
4
Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma.肝移植与肝切除术治疗肝细胞癌。
J Surg Oncol. 2010 Jan 1;101(1):47-53. doi: 10.1002/jso.21415.
5
Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis.肝硬化患者单发肝癌:肝切除术还是肝移植?基于意向治疗的长期结果。
Ann Surg Oncol. 2013 Apr;20(4):1194-202. doi: 10.1245/s10434-012-2655-1. Epub 2012 Sep 11.
6
Liver transplantation for hepatocellular carcinoma recurrence after liver resection: why deny this chance of cure?肝切除术后肝癌复发行肝移植:为何拒绝这一治愈机会?
J Clin Gastroenterol. 2013 Apr;47(4):352-8. doi: 10.1097/MCG.0b013e31826e6caf.
7
Resection prior to liver transplantation for hepatocellular carcinoma.肝细胞癌肝移植前的切除术。
Ann Surg. 2003 Dec;238(6):885-92; discussion 892-3. doi: 10.1097/01.sla.0000098621.74851.65.
8
Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma.复发性肝细胞癌患者挽救性肝移植的可行性
Clin Transplant. 2005 Apr;19(2):175-80. doi: 10.1111/j.1399-0012.2005.00277.x.
9
Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation.对于符合肝移植条件的Child-Turcotte-Pugh A级肝硬化肝细胞癌患者,肝切除术是一个不错的选择。
Liver Transpl. 2005 Oct;11(10):1242-51. doi: 10.1002/lt.20398.
10
[Liver transplantation for hepatocellular carcinoma: prognostic analysis of 89 cases].[肝细胞癌肝移植:89例预后分析]
Zhonghua Wai Ke Za Zhi. 2005 Apr 1;43(7):450-4.

引用本文的文献

1
Long-Term Survival and Recurrence After Liver Transplantation Versus Resection in Cirrhotic Hepatocellular Carcinoma: A Systematic Review.肝硬化肝细胞癌肝移植与肝切除术后的长期生存和复发:一项系统评价
Cureus. 2025 May 3;17(5):e83418. doi: 10.7759/cureus.83418. eCollection 2025 May.
2
Liver transplantation vs liver resection in HCC: promoting extensive collaborative research through a survival meta-analysis of meta-analyses.肝细胞癌肝移植与肝切除术的比较:通过荟萃分析的生存荟萃分析促进广泛的合作研究。
Front Oncol. 2024 Mar 18;14:1366607. doi: 10.3389/fonc.2024.1366607. eCollection 2024.
3
Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives.肝切除术后及热消融后肝细胞癌复发的管理:现状与未来展望
Hepatobiliary Surg Nutr. 2024 Feb 1;13(1):71-88. doi: 10.21037/hbsn-22-579. Epub 2023 Jun 19.
4
Primary versus Salvage Liver Transplantation after Curative-Intent Resection or Radiofrequency Ablation for Hepatocellular Carcinoma: Long-Term Oncological Outcomes.肝细胞癌根治性切除或射频消融术后原发性肝移植与挽救性肝移植:长期肿瘤学结局
Cancers (Basel). 2023 Oct 18;15(20):5030. doi: 10.3390/cancers15205030.
5
Surgical Strategies for Recurrent Hepatocellular Carcinoma after Resection: A Review of Current Evidence.肝切除术后复发性肝细胞癌的手术策略:当前证据综述
Cancers (Basel). 2023 Jan 13;15(2):508. doi: 10.3390/cancers15020508.
6
Salvage versus Primary Liver Transplantation for Hepatocellular Carcinoma: A Twenty-Year Experience Meta-Analysis.肝细胞癌挽救性肝移植与原位肝移植:一项二十年经验的荟萃分析
Cancers (Basel). 2022 Jul 16;14(14):3465. doi: 10.3390/cancers14143465.
7
Surgical management of hepatocellular carcinoma-Western versus Eastern attitude.肝细胞癌的外科治疗——西方与东方的态度
Transl Cancer Res. 2019 Apr;8(Suppl 3):S245-S260. doi: 10.21037/tcr.2018.12.28.
8
Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma.非 HCV/非 HBV 肝细胞癌患者循环和肿瘤浸润免疫细胞的高度差异计数。
Cancer Immunol Immunother. 2022 May;71(5):1103-1113. doi: 10.1007/s00262-021-03061-9. Epub 2021 Sep 28.
9
The Impact of Time Interval between Hepatic Resection and Liver Transplantation on Clinical Outcome in Patients with Hepatocellular Carcinoma.肝切除与肝移植时间间隔对肝细胞癌患者临床结局的影响
Cancers (Basel). 2021 May 15;13(10):2398. doi: 10.3390/cancers13102398.
10
Repeat liver resection versus salvage liver transplant for recurrent hepatocellular carcinoma: A propensity score-adjusted and -matched comparison analysis.复发性肝细胞癌的再次肝切除与挽救性肝移植:倾向评分调整匹配比较分析
Ann Hepatobiliary Pancreat Surg. 2019 Nov;23(4):305-312. doi: 10.14701/ahbps.2019.23.4.305. Epub 2019 Nov 29.

本文引用的文献

1
Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence.肝硬化患者肝细胞癌肝切除术后肝内复发危险因素的单因素及多因素分析
Ann Surg. 2003 Apr;237(4):536-43. doi: 10.1097/01.SLA.0000059988.22416.F2.
2
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.肝切除术后肝细胞癌早期和晚期肝内复发的危险因素。
J Hepatol. 2003 Feb;38(2):200-7. doi: 10.1016/s0168-8278(02)00360-4.
3
Hepatocellular carcinoma: diagnosis and treatment.肝细胞癌:诊断与治疗
Gastroenterology. 2002 May;122(6):1609-19. doi: 10.1053/gast.2002.33411.
4
Preoperative predictors of survival after resection of small hepatocellular carcinomas.小肝细胞癌切除术后生存的术前预测因素。
Ann Surg. 2002 May;235(5):722-30; discussion 730-1. doi: 10.1097/00000658-200205000-00015.
5
Current status of liver transplantation for hepatocellular cancer.肝细胞癌肝移植的现状
Am J Surg. 2002 Mar;183(3):309-16. doi: 10.1016/s0002-9610(02)00785-7.
6
Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation.肝功能良好的小肝细胞癌患者切除术后的长期生存及复发模式:对挽救性肝移植策略的启示
Ann Surg. 2002 Mar;235(3):373-82. doi: 10.1097/00000658-200203000-00009.
7
Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.肝移植等待名单期间肝细胞癌辅助治疗的成本效益
Gut. 2002 Jan;50(1):123-8. doi: 10.1136/gut.50.1.123.
8
Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis.活体供肝与尸体供肝肝移植治疗不可切除小肝细胞癌合并代偿期肝硬化的决策分析
Transplantation. 2001 Sep 15;72(5):861-8. doi: 10.1097/00007890-200109150-00021.
9
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.肝细胞癌的肝移植:肿瘤大小限制的放宽不会对生存率产生不利影响。
Hepatology. 2001 Jun;33(6):1394-403. doi: 10.1053/jhep.2001.24563.
10
Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective.活体供肝肝移植治疗早期肝细胞癌:从预期寿命和成本效益角度分析
Hepatology. 2001 May;33(5):1073-9. doi: 10.1053/jhep.2001.23311.

肝切除术作为肝硬化合并肝细胞癌患者肝移植的过渡手段:一种合理的策略?

Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?

作者信息

Adam René, Azoulay Daniel, Castaing Denis, Eshkenazy Rony, Pascal Gérard, Hashizume Kentaro, Samuel Didier, Bismuth Henri

机构信息

Centre Hépato-Biliare, Hospital Paul Brousse, Assistance Publique, Hospitaux de Paris Université Paris-Sud Villejuif, France.

出版信息

Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9. doi: 10.1097/01.sla.0000090449.87109.44.

DOI:10.1097/01.sla.0000090449.87109.44
PMID:14530722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1360109/
Abstract

OBJECTIVE

To assess the viability of a strategy of primary resection with secondary liver transplantation (LT) for hepatocellular carcinoma (HCC) on cirrhosis.

SUMMARY BACKGROUND DATA

LT is the optimal treatment of HCC with cirrhosis. Owing to organ shortage, liver resection is considered as a reasonable first-line treatment of patients with small HCC and good liver function, with secondary LT as a perspective in case of recurrence. The viability of such strategy, positively explored in theoretical models, is not documented in clinical practice.

METHODS

Among 358 consecutive patients with HCC on cirrhosis treated by liver resection (n = 163; 98 of whom were transplantable) or transplantation (n = 195), the feasibility and outcome of secondary transplantation was evaluated in a 2-step fashion. First, secondary LT for tumor recurrence after resection (n = 17) was compared with primary LT (n = 195), to assess the risk and the outcome of secondary LT in patients who effectively succeeded to be treated by this approach. Second, primary resection in transplantable patients (n = 98) was compared with that of primary LT (n = 195) on an intention-to-treat basis, to assess the outcome of each treatment strategy and to determine the proportion of resected patients likely to be switched for secondary LT. Transplantability of resected patients was retrospectively determined according to selection criteria of LT for HCC.

RESULTS

Operative mortality (< or =2 months) of secondary LT was significantly higher than that of primary LT (28.6% versus 2.1%; P = 0.0008) as was intraoperative bleeding (mean transfused blood units, 20.7 versus 10.5; P = 0.0001). Tumor recurrence occurred more frequently after secondary than after primary LT (54% versus 18%; P = 0.001). Posttransplant 5-year overall survival was 41% versus 61% (P = 0.03), and disease-free survival was 29% versus 58% (P = 0.003) for secondary and primary LT, respectively. Of 98 patients treated by resection while initially eligible for transplantation, only 20 (20%) were secondarily transplanted, 17 of whom (17%) for tumor recurrence and 3 (3%) for hepatic decompensation. Transplantability of tumoral recurrence was 25% (17 of 69 recurrences). Compared with primarily transplanted patients, transplantable resected patients had a decreased 5-year overall survival (50% versus 61%; P = 0.05) and disease-free survival (18% versus 58%; P < 0.0001), despite the use of secondary LT. On a multivariate analysis including 271 patients eligible for transplantation and treated by either liver resection or primary LT, liver resection alone (P < 0.0001; risk ratio [RR] = 3.27) or liver resection with secondary LT (P < 0.05; RR= 1.87) emerged as negative independent factors of disease-free survival as compared with primary LT. A number of nodules > 3 (P = 0.002; RR= 2.02) and a maximum tumor size exceeding 30 mm (P < 0.0001; RR=1.93) were also predictive of lower disease-free survival.

CONCLUSIONS

LT after liver resection is associated with a higher operative mortality, an increased risk of recurrence, and a poorer outcome than primary LT. In addition, liver resection as a bridge to LT impairs the patient transplantability and the chance of long-term survival of cirrhotic patients with HCC. Primary LT should therefore remain the ideal choice of treatment of a cirrhotic patient with HCC, even when the tumor is resectable.

摘要

目的

评估原发性肝癌伴肝硬化患者行一期肝切除联合二期肝移植(LT)策略的可行性。

总结背景资料

LT是治疗肝癌伴肝硬化的最佳方法。由于器官短缺,肝切除被认为是肝功能良好的小肝癌患者合理的一线治疗方法,二期LT作为复发时的一种选择。这种策略在理论模型中得到了积极探索,但在临床实践中尚无文献记载。

方法

在358例连续接受肝切除(n = 163;其中98例适合移植)或移植(n = 195)治疗的肝癌伴肝硬化患者中,分两步评估二期移植的可行性和结果。首先,将肝切除术后肿瘤复发患者的二期LT(n = 17)与一期LT(n = 195)进行比较,以评估有效接受该方法治疗的患者二期LT的风险和结果。其次,在意向性治疗基础上,将适合移植患者的一期肝切除(n = 98)与一期LT(n = 195)进行比较,以评估每种治疗策略的结果,并确定可能转为二期LT的肝切除患者比例。根据肝癌LT的选择标准,回顾性确定肝切除患者的可移植性。

结果

二期LT的手术死亡率(≤2个月)显著高于一期LT(28.6%对2.1%;P = 0.0008),术中出血量也更高(平均输血量,20.7对10.5;P = 0.0001)。二期LT后肿瘤复发比一期LT更频繁(54%对18%;P = 0.001)。二期和一期LT的移植后5年总生存率分别为41%对61%(P = 0.03),无病生存率分别为29%对58%(P = 0.003)。在98例最初适合移植但接受肝切除治疗的患者中,只有20例(20%)接受了二期移植,其中17例(17%)因肿瘤复发,3例(3%)因肝失代偿。肿瘤复发的可移植性为25%(69例复发中的17例)。与一期移植患者相比,可移植的肝切除患者5年总生存率(50%对61%;P = 0.05)和无病生存率(18%对58%;P < 0.0001)降低,尽管采用了二期LT。在一项包括271例适合移植并接受肝切除或一期LT治疗的患者的多变量分析中,与一期LT相比,单纯肝切除(P < 0.0001;风险比[RR] = 3.27)或肝切除联合二期LT(P < 0.05;RR = 1.87)是无病生存的负面独立因素。结节数>3个(P = 0.002;RR = 2.02)和最大肿瘤大小超过30 mm(P < 0.0001;RR = 1.93)也预示着无病生存率较低。

结论

肝切除术后LT与更高的手术死亡率、更高的复发风险以及比一期LT更差的结果相关。此外,作为LT桥梁的肝切除会损害患者的可移植性和肝癌伴肝硬化患者的长期生存机会。因此,即使肿瘤可切除,一期LT仍应是肝癌伴肝硬化患者的理想治疗选择。